keyword
MENU ▼
Read by QxMD icon Read
search

Non-alcoholic fatty liver disease

keyword
https://www.readbyqxmd.com/read/29244873/fatty-acids-in-non-alcoholic-steatohepatitis-focus-on-pentadecanoic-acid
#1
Wonbeak Yoo, Donjeta Gjuka, Heather L Stevenson, Xiaoling Song, Hong Shen, Suk Young Yoo, Jing Wang, Michael Fallon, George N Ioannou, Stephen A Harrison, Laura Beretta
Non-alcoholic fatty liver disease (NAFLD) is the most common form of liver disease and ranges from isolated steatosis to NASH. To determine whether circulating fatty acids could serve as diagnostic markers of NAFLD severity and whether specific fatty acids could contribute to the pathogenesis of NASH, we analyzed two independent NAFLD patient cohorts and used the methionine- and choline-deficient diet (MCD) NASH mouse model. We identified six fatty acids that could serve as non-invasive markers of NASH in patients with NAFLD...
2017: PloS One
https://www.readbyqxmd.com/read/29243418/-research-progress-of-pharmacokinetics-and-pharmacodynamics-of-total-glucosides-of-peony-in-hepatoprotective-effects
#2
REVIEW
Zhi-Yan Zuo, Shu-Yu Zhan, Xuan Huang, Bao-Yue Ding, Yu-Qian Liu, Yu-Er Ruan, Ning-Hua Jiang
Total glucosides of peony (TGP), containing the effective components of paeoniflorin (Pae), albiflorin (Alb) and so on, are effective parts of Radix Paeoniae Alba. And it possesses extensive pharmacological actions, one of which is hepatoprotective effect. In recent years, abundant of pharmacokinetics and pharmacodynamics research of TGP in hepatoprotective effects have been performed. However, the relative medicine of TGP in hepatoprotective effect has not been developed for clinical application. In order to provide reference for the development and rational clinical application of TGP, the research progresses of pharmacokinetics and pharmacodynamics of TGP in hepatoprotective effect were summarized in this paper...
October 2017: Zhongguo Zhong Yao za Zhi, Zhongguo Zhongyao Zazhi, China Journal of Chinese Materia Medica
https://www.readbyqxmd.com/read/29238323/relationship-between-hypothyroidism-and-non-alcoholic-fatty-liver-disease-a-systematic-review-and-meta-analysis
#3
Weiwei He, Xiaofei An, Ling Li, Xiaoqing Shao, Qian Li, Qiuming Yao, Jin-An Zhang
Background: Previous studies propose that hypothyroidism might play a crucial role in the pathogenesis of non-alcoholic fatty liver disease (NAFLD), but findings from published studies on the relationship between hypothyroidism and NAFLD are still controversial. Our study aimed to make a comprehensive evaluation of the relationship between hypothyroidism and NAFLD through a meta-analysis. Methods: PubMed, China Dissertation Database, and EMBASE databases were searched to find observational studies assessing the relationship between hypothyroidism and NAFLD...
2017: Frontiers in Endocrinology
https://www.readbyqxmd.com/read/29237547/non-alcoholic-fatty-liver-disease-a-risk-factor-for-myocardial-dysfunction
#4
EDITORIAL
Christopher D Byrne, Gianluca Perseghin
No abstract text is available yet for this article.
December 10, 2017: Journal of Hepatology
https://www.readbyqxmd.com/read/29234634/association-of-serum-ferritin-with-diabetes-and-alcohol-in-patients-with-non-viral-liver-disease-related-hepatocellular-carcinoma
#5
Rohan C Siriwardana, Madunil A Niriella, Anuradha Dassanayake, Dileepa Ediriweera, Bhagya Gunetilleke, Thenuka Sivasundaram, Janaka de Silva
INTRODUCTION: Non-alcoholic fatty liver disease is a leading cause for hepatocellular carcinoma (HCC) in Sri Lanka. Diabetes mellitus, alcohol abuse, and liver inflammation are known to increase the risk of HCC. The present study evaluates serum ferritin levels in a cohort of patients with non-viral HCC (nvHCC). METHODOLOGY: Consecutive patients with nvHCC presenting to the Colombo North Liver transplant Service, Ragama, from January 2012 to July 2013 were investigated...
November 2017: Liver Cancer
https://www.readbyqxmd.com/read/29234288/lipocalin-2-in-fructose-induced-fatty-liver-disease
#6
Jessica Lambertz, Thorsten Berger, Tak W Mak, Josef van Helden, Ralf Weiskirchen
The intake of excess dietary fructose most often leads to non-alcoholic fatty liver disease (NAFLD). Fructose is metabolized mainly in the liver and its chronic consumption results in lipogenic gene expression in this organ. However, precisely how fructose is involved in NAFLD progression is still not fully understood, limiting therapy. Lipocalin-2 (LCN2) is a small secreted transport protein that binds to fatty acids, phospholipids, steroids, retinol, and pheromones. LCN2 regulates lipid and energy metabolism in obesity and is upregulated in response to insulin...
2017: Frontiers in Physiology
https://www.readbyqxmd.com/read/29234195/simple-anthropometric-indices-are-useful-for-predicting-non-alcoholic-fatty-liver-disease-nafld-in-asian-indians
#7
Ayaskanta Singh, Sasmita Parida, Jimmy Narayan, Preetam Nath, Pradeep K Padhi, Girish K Pati, Prasanta K Parida, Chudamani Meher, Omprakash Agrawal, Shivaram P Singh
Background and aims: With the rising prevalence of obesity and metabolic syndrome, nonalcoholic fatty liver disease (NAFLD) has become the most common liver disorder in both developed and developing nations. Several studies on NAFLD have described waist circumference, a surrogate marker of visceral fat accumulation and waist height ratio as a better screening tool for NAFLD and metabolic syndrome than body mass index (BMI). We conducted this study to assess simple abdominal obesity indices as a predictor of NAFLD and determine the appropriate cut-off levels with reference to NAFLD...
December 2017: Journal of Clinical and Experimental Hepatology
https://www.readbyqxmd.com/read/29232562/tm6sf2-a-novel-target-for-plasma-lipid-regulation
#8
REVIEW
Ting-Ting Li, Tao-Hua Li, Juan Peng, Bei He, Lu-Shan Liu, Dang-Heng Wei, Zhi-Sheng Jiang, Xi-Long Zheng, Zhi-Han Tang
Transmembrane 6 superfamily 2 (TM6SF2), a gene identified at the locus 19p12, has been recognized to regulate plasma lipids. Here, we provide an overview of the roles of TM6SF2 as a novel target for plasma lipid regulation. We first review the association of TM6SF2 variant with plasma lipid traits, cardiovascular disease (CVD) and non-alcoholic fatty liver disease (NAFLD). Then, we present an overview about the in vivo validation of TM6SF2 as a regulator of plasma lipid levels using mice, with overexpression or knockdown/knockout of TM6SF2...
December 1, 2017: Atherosclerosis
https://www.readbyqxmd.com/read/29231919/-non-alcoholic-liver-disease-diagnosis-and-treatment
#9
REVIEW
Anna Sarosiekjeznach-Steinhagen, Joanna Ostrowska, Aneta Czerwonogrodzka-Senczyna, Iwona Boniecka
Non-alcoholic fatty liver disease (NAFLD) is currently the most common chronic liver disease in the developed world (15% to 40% of the adult population). Introduction of lifestyle changes including dietary intervention and increased physical activity is most often the first-line treatment and is intended to support not only the treatment of liver disease, but also for diseases associated with obesity, insulin resistance, diabetes and dyslipidemia. In addition to well-known metformin, there are new classes of antidiabetic drugs, including GLP-1analog, SGLT-2 antagonist, pioglitazon...
November 23, 2017: Polski Merkuriusz Lekarski: Organ Polskiego Towarzystwa Lekarskiego
https://www.readbyqxmd.com/read/29228666/granulocyte-colony-stimulating-factor-treatment-in-non-alcoholic-fatty-liver-disease-beyond-marrow-cell-mobilization
#10
Ho Hyun Nam, Dae Won Jun, Kiseok Jang, Waqar Khalid Saeed, Jai Sun Lee, Hyeon Tae Kang, Yeon Ji Chae
Protective effects of granulocyte colony stimulating factor (G-CSF) in acute liver injury via marrow cell mobilization have been reported in several studies. But exact mode of action and optimal protocol of G-CSF has been still doubt in chronic disease. Here we investigated mode of action and optimization of G-CSF as a treatment for non-alcoholic fatty liver disease (NAFLD). Various doses of conventional G-CSF (30 μg/kg once weekly, once daily for 5 days, twice weekly) and long acting G-CSF (30 μg/kg once a month) were evaluated in two kinds of NAFLD animal models to optimize the G-CSF protocol...
November 17, 2017: Oncotarget
https://www.readbyqxmd.com/read/29228164/liver-fat-content-non-alcoholic-fatty-liver-disease-and-ischaemic-heart-disease-mendelian-randomization-and-meta-analysis-of-279%C3%A2-013-individuals
#11
Bo Kobberø Lauridsen, Stefan Stender, Thomas Skårup Kristensen, Klaus Fuglsang Kofoed, Lars Køber, Børge G Nordestgaard, Anne Tybjærg-Hansen
Aims: In observational studies, non-alcoholic fatty liver disease (NAFLD) is associated with high risk of ischaemic heart disease (IHD). We tested the hypothesis that a high liver fat content or a diagnosis of NAFLD is a causal risk factor for IHD. Methods and results: In a cohort study of the Danish general population (n = 94 708/IHD = 10 897), we first tested whether a high liver fat content or a diagnosis of NAFLD was associated observationally with IHD...
December 8, 2017: European Heart Journal
https://www.readbyqxmd.com/read/29226105/non-alcoholic-fatty-liver-disease-a-clinical-update
#12
REVIEW
Joseph M Pappachan, Shithu Babu, Babu Krishnan, Nishal C Ravindran
Non-alcoholic fatty liver disease (NAFLD) is currently the most common chronic liver disease in developed countries because of the obesity epidemic. The disease increases liver-related morbidity and mortality, and often increases the risk for other comorbidities, such as type 2 diabetes and cardiovascular disease. Insulin resistance related to metabolic syndrome is the main pathogenic trigger that, in association with adverse genetic, humoral, hormonal and lifestyle factors, precipitates development of NAFLD...
December 28, 2017: Journal of Clinical and Translational Hepatology
https://www.readbyqxmd.com/read/29225776/the-sedentary-r-evolution-have-we-lost-our-metabolic-flexibility
#13
Jens Freese, Rainer Johannes Klement, Begoña Ruiz-Núñez, Sebastian Schwarz, Helmut Lötzerich
During the course of evolution, up until the agricultural revolution, environmental fluctuations forced the human species to develop a flexible metabolism in order to adapt its energy needs to various climate, seasonal and vegetation conditions. Metabolic flexibility safeguarded human survival independent of food availability. In modern times, humans switched their primal lifestyle towards a constant availability of energy-dense, yet often nutrient-deficient, foods, persistent psycho-emotional stressors and a lack of exercise...
2017: F1000Research
https://www.readbyqxmd.com/read/29223443/response-to-pioglitazone-in-patients-with-nonalcoholic-steatohepatitis-with-vs-without-type-2-diabetes
#14
Fernando Bril, Srilaxmi Kalavalapalli, Virginia C Clark, Romina Lomonaco, Consuelo Soldevila-Pico, I-Chia Liu, Beverly Orsak, Fermin Tio, Kenneth Cusi
BACKGROUND & AIMS: Pioglitazone is effective for long-term treatment of patients with nonalcoholic steatohepatitis (NASH) with prediabetes or type-2 diabetes. However, it is not clear how the presence of type-2 diabetes affects the drug's efficacy. We compared metabolic and histologic responses to pioglitazone in patients with NASH and prediabetes vs type-2 diabetes. METHODS: We performed a prospective study of adults with biopsy-proven NASH (52 with type-2 diabetes and 49 with prediabetes), enrolled from the general population of San Antonio, Texas from 2008 through 2014...
December 6, 2017: Clinical Gastroenterology and Hepatology
https://www.readbyqxmd.com/read/29222917/diagnostic-modalities-for-non-alcoholic-fatty-liver-disease-nafld-non-alcoholic-steatohepatitis-nash-and-associated-fibrosis
#15
REVIEW
Zobair M Younossi, Rohit Loomba, Quentin M Anstee, Mary E Rinella, Elisabetta Bugianesi, Giulio Marchesini, Brent A Neuschwander-Tetri, Lawrence Serfaty, Francesco Negro, Stephen H Caldwell, Vlad Ratziu, Kathleen E Corey, Scott L Friedman, Manal F Abdelmalek, Stephen A Harrison, Arun J Sanyal, Joel E Lavine, Philippe Mathurin, Michael R Charlton, Zachary D Goodman, Naga P Chalasani, Kris V Kowdley, Jacob George, Keith Lindor
NAFLD is a spectrum comprised of isolated steatosis, NASH, advanced fibrosis, and cirrhosis. The majority of NAFLD subjects do not have NASH and don't carry a significant risk for adverse outcomes (cirrhosis and mortality). Globally, the prevalence of NAFLD is approximately 25%. In Asia, a gradient of high prevalence rates to low rates are noted from urban to rural areas. Given the prevalence of NAFLD, the clinical and economic burden of NAFLD and NASH can be substantial. With increasing recognition as an important liver disease, the diagnosis of NASH still requires a liver biopsy which is suboptimal...
December 9, 2017: Hepatology: Official Journal of the American Association for the Study of Liver Diseases
https://www.readbyqxmd.com/read/29222911/current-and-future-therapeutic-regimens-for-non-alcoholic-fatty-liver-disease-nafld-and-non-alcoholic-steatohepatitis-nash
#16
REVIEW
Zobair M Younossi, Rohit Loomba, Mary E Rinella, Elisabetta Bugianesi, Giulio Marchesini, Brent A Neuschwander-Tetri, Lawrence Serfaty, Francesco Negro, Stephen H Caldwell, Vlad Ratziu, Kathleen E Corey, Scott L Friedman, Manal F Abdelmalek, Stephen A Harrison, Arun J Sanyal, Joel E Lavine, Philippe Mathurin, Michael R Charlton, Naga P Chalasani, Quentin M Anstee, Kris V Kowdley, Jacob George, Zachary D Goodman, Keith Lindor
NASH/NAFLD is rapidly becoming one of top causes of cirrhosis, hepatocellular carcinoma and indication for liver transplantation. Except for life style modification through diet and exercise, there are currently no other approved treatments for NASH/NAFLD. Although weight loss can be effective, it is hard to achieve and sustain. In contrast, bariatric surgery can improve metabolic conditions associated with NAFLD and has been shown to improve liver histology. In order to have approved regimens for treatment of NASH/NAFLD, a number of issues that must be addressed...
December 9, 2017: Hepatology: Official Journal of the American Association for the Study of Liver Diseases
https://www.readbyqxmd.com/read/29222767/platelet-counts-and-liver-enzymes-after-gastric-bypass-surgery
#17
Hans-Erik Johansson, Anna Wåhlén, Erica Aldenbäck, Arvo Haenni
BACKGROUND: Obesity is associated with chronic inflammation, liver steatosis and increased liver enzymes such as gamma-glutamyltransferase (GGT) and alanine aminotransferase (ALT), markers for non-alcoholic fatty liver disease (NAFLD) and liver fat content. Increased platelet counts (PCs) are a biomarker reflecting inflammation and the degree of fibrosis in NAFLD. We investigated alterations in PCs, GGT, ALT, C-reactive protein (CRP) and ferritin after Roux-en-Y gastric bypass (RYGBP)...
December 8, 2017: Obesity Surgery
https://www.readbyqxmd.com/read/29222051/long-term-fermented-soybean-paste-improves-metabolic-parameters-associated-with-non-alcoholic-fatty-liver-disease-and-insulin-resistance-in-high-fat-diet-induced-obese-mice
#18
Min-Seok Kim, Bobae Kim, Haryung Park, Yosep Ji, Wilhelm Holzapfel, Do-Young Kim, Chang-Kee Hyun
Recently, Korean traditional fermented soybean paste, called Doenjang, has attracted attention for its protective effect against diet-related chronic diseases such as obesity and type 2 diabetes. Long-term fermented soybean pastes (LFSPs) are made by fermentation with naturally-occurring microorganisms for several months, whereas short-term fermented soybean pastes (SFSPs) are produced by shorter-time fermentation inoculated with a starter culture. Here, we demonstrate that administration of LFSP, but not SFSP, protects high-fat diet (HFD)-fed obese mice against non-alcohol fatty liver disease (NAFLD) and insulin resistance...
December 5, 2017: Biochemical and Biophysical Research Communications
https://www.readbyqxmd.com/read/29221790/fam3-gene-family-a-promising-therapeutical-target-for-nafld-and-type-2-diabetes
#19
REVIEW
Zhang Xiaoyan, Weili Yang, Junpei Wang, Yuhong Meng, Youfei Guan, Jichun Yang
Non-alcoholic fatty liver disease (NAFLD) and diabetes are severe public health issues worldwide. The Family with sequence similarity 3 (FAM3) gene family consists of four members designated as FAM3A, FAM3B, FAM3C and FAM3D, respectively. Recently, there had been increasing evidence that FAM3A, FAM3B and FAM3C are important regulators of glucose and lipid metabolism. FAM3A expression is reduced in the livers of diabetic rodents and NAFLD patients. Hepatic FAM3A restoration activates ATP-P2 receptor-Akt and AMPK pathways to attenuate steatosis and hyperglycemia in obese diabetic mice...
December 5, 2017: Metabolism: Clinical and Experimental
https://www.readbyqxmd.com/read/29220869/non-obese-fatty-liver-disease-is-associated-with-lacunar-infarct
#20
Min-Sun Kwak, Kyung Won Kim, Hyobin Seo, Goh-Eun Chung, Jeong Yoon Yim, Donghee Kim
BACKGROUND/AIMS: Lacunar infarct, a small subcortical ischemic lesion, is a known risk factor for future cognitive impairment, dementia, and stroke. We evaluated the relationship between fatty liver disease(FLD) and lacunar infarct in a healthy general population. METHODS: Subjects who underwent brain magnetic resonance imaging(MRI) and abdominal ultrasonography(US) during health check-ups from 2007-2009 were included. FLD was diagnosed by US. Subjects with a history of cerebrovascular disease, radiological findings consistent with cerebrovascular stenosis, or cerebral small vessel disease were excluded...
December 8, 2017: Liver International: Official Journal of the International Association for the Study of the Liver
keyword
keyword
2051
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"